Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short-acting beta 2 agonists for stable COPD.

P Sestini1, E Renzoni, S Robinson

  • 1Institute of Respiratory Diseases, University of Siena, Viale Bracci 3, 53100, Siena, Italy. sestini@unisi.it

The Cochrane Database of Systematic Reviews
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asthma and allergies in schoolchildren: data from the European SINPHONIE study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic.

Pulmonology·2022
Same author

Effects of rituximab therapy on B cell differentiation and depletion.

Clinical rheumatology·2020
Same author

Omalizumab treatment in Samter's triad: case series and review of the literature.

European review for medical and pharmacological sciences·2019
Same author

NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Clinical and experimental medicine·2019
Same author

Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype?

Respiratory medicine case reports·2019
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Regular use of short-acting beta-2 agonists improves lung function and reduces breathlessness in Chronic Obstructive Pulmonary Disease (COPD) patients. Metered dose inhaler delivery showed benefits, though long-term side effects require further study.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) involves progressive airflow limitation.
  • Patients with stable COPD often experience symptomatic relief with short-acting bronchodilators despite limited reversibility.

Purpose of the Study:

  • To evaluate the clinical effectiveness of regular short-acting beta-2 agonist bronchodilator treatment in stable COPD.
  • To assess the adverse effects associated with this regular treatment.

Main Methods:

  • Conducted a systematic search of the Cochrane Airways Group database and reference lists.
  • Included randomized controlled trials (RCTs) of at least one week comparing short-acting beta-2 agonists (metered dose inhaler or nebulizer) with placebo in stable COPD patients.
  • Performed independent data extraction and quality assessment, contacting authors for missing information.

Related Experiment Videos

Main Results:

  • Thirteen high-quality, cross-over design studies were included.
  • Significant improvements in FEV1 (0.14 L) and PEFR were observed with metered dose inhaler delivery compared to placebo.
  • Patients reported reduced breathlessness (SMD=1.33) and preferred beta-2 agonist therapy (OR=9.04), with no significant improvement in exercise performance.
  • Treatment failure was less likely with beta-2 agonists than placebo (RR=0.49).

Conclusions:

  • Regular use of short-acting beta-2 agonists via metered dose inhaler improves lung function and breathlessness in stable COPD.
  • These medications are supported as first-line agents for symptomatic treatment of COPD.
  • Insufficient data exists to reliably assess long-term adverse effects.